Amgen annual operating income
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Amgen Operating Income Growth & History (AMGN)
Amgen's operating income was $9.08B for fiscal 2025.
View full Amgen company overviewAmgen annual operating income history
| Fiscal year | Period ended | Operating income | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $9.08B | $1.82B | +25.10% |
| 2024 | 2024-12-31 | $7.26B | −$639.0M | −8.09% |
| 2023 | 2023-12-31 | $7.90B | −$1.67B | −17.45% |
| 2022 | 2022-12-31 | $9.57B | $1.93B | +25.23% |
| 2021 | 2021-12-31 | $7.64B | −$1.50B | −16.41% |
| 2020 | 2020-12-31 | $9.14B | −$535.0M | −5.53% |
| 2019 | 2019-12-31 | $9.67B | −$589.0M | −5.74% |
| 2018 | 2018-12-31 | $10.26B | $290.0M | +2.91% |
| 2017 | 2017-12-31 | $9.97B | $179.0M | +1.83% |
| 2016 | 2016-12-31 | $9.79B | $1.32B | +15.63% |
| 2015 | 2015-12-31 | $8.47B | $2.28B | +36.81% |
| 2014 | 2014-12-31 | $6.19B | $324.0M | +5.52% |
| 2013 | 2013-12-31 | $5.87B | $290.0M | +5.20% |
| 2012 | 2012-12-31 | $5.58B | $1.26B | +29.34% |
| 2011 | 2011-12-31 | $4.31B | −$1.23B | −22.24% |
| 2010 | 2010-12-31 | $5.54B | $39.0M | +0.71% |
| 2009 | 2009-12-31 | $5.51B | $292.0M | +5.60% |
| 2008 | 2008-12-31 | $5.21B | $1.23B | +31.01% |
| 2007 | 2007-12-31 | $3.98B | — | — |
Amgen quarterly operating income
Q2.08
Q3.08
Q1.09
Q2.09
Q3.09
Q4.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating income | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $3.51B | $858.0M | +32.30% |
| Q1 2026 | 2026-03-31 | $2.67B | $1.49B | +126.32% |
| Q4 2025 | 2025-12-31 | $2.72B | $409.0M | +17.70% |
| Q3 2025 | 2025-09-30 | $2.53B | $479.0M | +23.40% |
| Q2 2025 | 2025-06-30 | $2.66B | $747.0M | +39.13% |
| Q1 2025 | 2025-03-31 | $1.18B | $187.0M | +18.87% |
| Q4 2024 | 2024-12-31 | $2.31B | $1.04B | +81.83% |
| Q3 2024 | 2024-09-30 | $2.05B | $26.0M | +1.29% |
| Q2 2024 | 2024-06-30 | $1.91B | −$775.0M | −28.87% |
| Q1 2024 | 2024-03-31 | $991.0M | −$930.0M | −48.41% |
| Q4 2023 | 2023-12-31 | $1.27B | −$959.0M | −43.00% |
| Q3 2023 | 2023-09-30 | $2.02B | −$639.0M | −24.02% |
| Q2 2023 | 2023-06-30 | $2.68B | $508.0M | +23.35% |
| Q1 2023 | 2023-03-31 | $1.92B | −$579.0M | −23.16% |
| Q4 2022 | 2022-12-31 | $2.23B | −$74.0M | −3.21% |
| Q3 2022 | 2022-09-30 | $2.66B | $282.0M | +11.86% |
| Q2 2022 | 2022-06-30 | $2.18B | $1.35B | +162.80% |
| Q1 2022 | 2022-03-31 | $2.50B | $371.0M | +17.43% |
| Q4 2021 | 2021-12-31 | $2.30B | $296.0M | +14.74% |
| Q3 2021 | 2021-09-30 | $2.38B | −$75.0M | −3.06% |
| Q2 2021 | 2021-06-30 | $828.0M | −$1.50B | −64.36% |
| Q1 2021 | 2021-03-31 | $2.13B | −$226.0M | −9.60% |
| Q4 2020 | 2020-12-31 | $2.01B | −$40.0M | −1.95% |
| Q3 2020 | 2020-09-30 | $2.45B | −$23.0M | −0.93% |
| Q2 2020 | 2020-06-30 | $2.32B | −$355.0M | −13.26% |
| Q1 2020 | 2020-03-31 | $2.35B | −$117.0M | −4.73% |
| Q4 2019 | 2019-12-31 | $2.05B | −$334.0M | −14.02% |
| Q3 2019 | 2019-09-30 | $2.48B | $153.0M | +6.59% |
| Q2 2019 | 2019-06-30 | $2.68B | −$154.0M | −5.44% |
| Q1 2019 | 2019-03-31 | $2.47B | −$254.0M | −9.32% |
| Q4 2018 | 2018-12-31 | $2.38B | $137.0M | +6.10% |
| Q3 2018 | 2018-09-30 | $2.32B | −$116.0M | −4.76% |
| Q2 2018 | 2018-06-30 | $2.83B | $134.0M | +4.97% |
| Q1 2018 | 2018-03-31 | $2.73B | $135.0M | +5.21% |
| Q4 2017 | 2017-12-31 | $2.25B | −$240.0M | −9.66% |
| Q3 2017 | 2017-09-30 | $2.44B | −$88.0M | −3.48% |
| Q2 2017 | 2017-06-30 | $2.70B | $318.0M | +13.36% |
| Q1 2017 | 2017-03-31 | $2.59B | $189.0M | +7.87% |
| Q4 2016 | 2016-12-31 | $2.48B | $452.0M | +22.23% |
| Q3 2016 | 2016-09-30 | $2.53B | $188.0M | +8.04% |
| Q2 2016 | 2016-06-30 | $2.38B | $304.0M | +14.64% |
| Q1 2016 | 2016-03-31 | $2.40B | $380.0M | +18.79% |
| Q4 2015 | 2015-12-31 | $2.03B | $574.0M | +39.34% |
| Q3 2015 | 2015-09-30 | $2.34B | $873.0M | +59.55% |
| Q2 2015 | 2015-06-30 | $2.08B | $174.0M | +9.15% |
| Q1 2015 | 2015-03-31 | $2.02B | $658.0M | +48.24% |
| Q4 2014 | 2014-12-31 | $1.46B | $272.0M | +22.91% |
| Q3 2014 | 2014-09-30 | $1.47B | −$222.0M | −13.15% |
| Q2 2014 | 2014-06-30 | $1.90B | $352.0M | +22.71% |
| Q1 2014 | 2014-03-31 | $1.36B | −$78.0M | −5.41% |
| Q4 2013 | 2013-12-31 | $1.19B | $99.0M | +9.10% |
| Q3 2013 | 2013-09-30 | $1.69B | $265.0M | +18.62% |
| Q2 2013 | 2013-06-30 | $1.55B | −$39.0M | −2.45% |
| Q1 2013 | 2013-03-31 | $1.44B | −$35.0M | −2.37% |
| Q4 2012 | 2012-12-31 | $1.09B | −$74.0M | −6.37% |
| Q3 2012 | 2012-09-30 | $1.42B | $898.0M | +171.05% |
| Q2 2012 | 2012-06-30 | $1.59B | $257.0M | +19.29% |
| Q1 2012 | 2012-03-31 | $1.48B | $184.0M | +14.23% |
| Q4 2011 | 2011-12-31 | $1.16B | $94.0M | +8.80% |
| Q3 2011 | 2011-09-30 | $525.0M | −$954.0M | −64.50% |
| Q2 2011 | 2011-06-30 | $1.33B | −$185.0M | −12.20% |
| Q1 2011 | 2011-03-31 | $1.29B | −$188.0M | −12.69% |
| Q4 2010 | 2010-12-31 | $1.07B | −$55.0M | −4.90% |
| Q3 2010 | 2010-09-30 | $1.48B | −$126.0M | −7.85% |
| Q2 2010 | 2010-06-30 | $1.52B | $60.0M | +4.12% |
| Q1 2010 | 2010-03-31 | $1.48B | $160.0M | +12.11% |
| Q4 2009 | 2009-12-31 | $1.12B | — | — |
| Q3 2009 | 2009-09-30 | $1.60B | $122.0M | +8.23% |
| Q2 2009 | 2009-06-30 | $1.46B | $278.0M | +23.58% |
| Q1 2009 | 2009-03-31 | $1.32B | — | — |
| Q3 2008 | 2008-09-30 | $1.48B | — | — |
| Q2 2008 | 2008-06-30 | $1.18B | — | — |
Amgen operating income trends
Over the last five fiscal years, Amgen's operating income decreased from $9.14B to $9.08B, a change of −$59.0M. The latest reported quarter, Q2 2026, shows $3.51B.
About the metric
What operating income means
Operating income is the profit or loss a company generates from its core business after cost of revenue and operating expenses, but before non-operating items such as interest and income taxes.
Calculation and source
SEC-reported operating income
TickerStat standardizes operating income reported in company SEC filings for aligned fiscal periods. It is not adjusted EBIT, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Amgen source filings ↗Community posts
Amgen–AstraZeneca combination cuts lung-cancer mortality risk by 58%
Amgen ($AMGN) disclosed detailed Phase 3 results showing that adding Imdelltra to AstraZeneca ($AZN)’s Imfinzi reduced the risk of death by 58% in first-line maintenance treatment of extensive-stage small-cell lung cancer. Median overall su ...
